小剂量康柏西普治疗早产儿视网膜病变的应用价值

目的观察小剂量康柏西普治疗早产儿视网膜病变的应用价值。方法选取2019年1月至2020年1月郑州大学附属儿童医院收治的80例视网膜病变(ROP)患儿包括急进型后部ROP (AP-ROP)、阈值期ROP及阈值前Ⅰ型ROP,诊断均符合抗血管内皮生长因子(VEGF)治疗指征],根据治疗方法不同分为对照组38例,小剂量组42例,对照组使用0.25 mg/0.025 mL康柏西普治疗,小剂量组使用0.15 mg/0.015 mL剂量康柏西普治疗。记录两组治疗总有效率和屈光不正发生率;比较治疗前后眼压;记录两组不良反应发生率。结果两组临床治疗总有效率、屈光不正发生率差异均无统计学意义(P>0.05);治疗前两组眼压比较差异无统计学意义(P>0.05),治疗后对照组眼压高于小剂量组(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论小剂量康柏西普治疗早产儿视网膜病变的效果安全可靠,值得临床推广使用。

Application value of low-dose conbercept in treatment of retinopathy of prematurity

【Objective】 To observe the application value of low-dose conbercept in the treatment of retinopathy of prematurity.【Methods】 Totally 80 premature infants with retinopathy admitted to the hospital between January 2019 and January 2020 were enrolled(including AP-ROP, threshold stage ROP and type I ROP before threshold, the diagnosis was in line with anti-VEGF treatment indications). They were divided into control group(38 cases) and low dose group(42 cases) according to the treatment method. The control group was treated with 0.25 mg conbercept, and the low dose group was treated with 0.15 mg conbercept. The total response rates and refractive index in the two groups were recorded. Intraocular pressure of the two groups was compared before and after treatment, and the incidences of complications were recorded. 【Results】 Both doses were effective in the treatment of retinopathy of prematurity, and there was no statistically significant difference in refractive index(P<0.05). Before treatment, there was no statistically significant difference in intraocular pressure between the two groups, but the control group had higher intraocular pressure than the low dose group after treatment(P<0.05). There were no statistically significant differences in the incidences of adverse reactions between the two groups(P>0.05). 【Conclusion】 Low-dose conbercept is effective, safe and reliable in the treatment of retinopathy of prematurity.